原発性非小細胞肺癌におけるＥｐｉｄｅｒｍａｌ　Ｇｒｏｗｔｈ　Ｆａｃｔｏｒ　ｒｅｃｅｐｔｏｒの発現　Ａｓｓａｙ値と他の臨床パラメーターとの対比

DOI Web Site

書誌事項

タイトル別名
  • Relationship between Epidermal Growth Factor Receptor Expression and Various Prognostic Factors in Human Non-small Cell Lung Cancer.
  • Assay値と他の臨床パラメーターとの対比

この論文をさがす

抄録

The relationship between epidermal growth factor receptor (EGFr) expression and various prognostic factors was investigated in 50 samples of human non-small cell lung cancer tissues. EGFr was measured by competitive binding assay using 125I-EGF. The mean EGFr level was 31.83±44.07 (mean±sd) fmol/mg · p for all lung cancers, 21.25±18.99 in stage I, 13.20±12.85 in stage II, 41.28±69.27 in stage IIIA, 30.08±34.28 in stage III B, 57.67±63.50 in stage IV, 26.12±33.21 for cancers without lymph node metastasis, 14.88±12.75 for cancers with hilar lymph node metastasis and 54.55±65.14 for cancers with mediastinal lymph node metastasis. The mean EGFr concentration was significantly higher in stage IV than in stage I, and the same significant difference was found between advanced stages (III and N) (45.31±58.53) and early stages (I and II) (19.39±17.86) too (p≤0.05). A tendency toward a possible relationship between receptor concentrations and lymph node status was found; the mean EGFr concentration was significantly higher in cases with advanced lymph node status (2 and 3) than in cases with early lymph node status (0 and 1) (23.00±29.25), while no relationship was observed between receptor concentrations and tumor size. No relationships were found between receptor concentrations and histological tumor type, gender and patient age. These data suggest that EGFr status may be important in the prediction of biologically high malignant potential.

収録刊行物

  • 肺癌

    肺癌 34 (1), 89-94, 1994

    特定非営利活動法人 日本肺癌学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ